| 1.4396 -0.94 (-39.51%) | 11-29 11:14 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 2.18  |
1-year : | 3.46 |
| Resists | First : | 1.87 |
Second : | 2.97 |
| Pivot price | 0.37 |
|||
| Supports | First : | 0.1 |
Second : | 0.08 |
| MAs | MA(5) : | 0.84 |
MA(20) : | 0.32 |
| MA(100) : | 0.74 |
MA(250) : | 0.81 |
|
| MACD | MACD : | 0.2 |
Signal : | 0 |
| %K %D | K(14,3) : | 43.3 |
D(3) : | 38.2 |
| RSI | RSI(14): 67.1 |
|||
| 52-week | High : | 2.97 | Low : | 0.1 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ SEEL ] has closed below upper band by 7.2%. Bollinger Bands are 452.7% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 1 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 2.97 - 2.99 | 2.99 - 3 |
| Low: | 2.21 - 2.22 | 2.22 - 2.23 |
| Close: | 2.36 - 2.38 | 2.38 - 2.4 |
Seelos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of central nervous system, respiratory, and other disorders. The company's lead programs are SLS-002, an intranasal racemic ketamine for the treatment of acute suicidal ideation and behavior in patients with major depressive disorders; SLS-005, a protein stabilizer for the treatment of amyotrophic lateral sclerosis and Sanfilippo syndrome; and SLS-006, a partial dopamine agonist for the treatment of patients with Parkinson's disease (PD). Its preclinical programs include SLS-007, an anti-alpha-synuclein peptidic inhibitor to treat patients with PD; SLS-008, an orally available antagonist for chemoattractant receptor-homologous molecule for the treatment of chronic inflammation in asthma and pediatric orphan indications; SLS-004 for the treatment of PD; SLS-010, an oral histamine H3A receptor antagonist for narcolepsy and related disorders; and SLS-012, an injectable therapy for post-operative pain management. Seelos Therapeutics, Inc. was incorporated in 1987 and is headquartered in New York, New York.
Wed, 29 Nov 2023
Why Workday Shares Are Trading Higher By Around 9%; Here Are ... - Investing.com UK
Wed, 29 Nov 2023
Seelos Therapeutics Announces Pricing of $5.55 Million Public Offering - BioSpace
Tue, 28 Nov 2023
Seelos Therapeutics Announces Pricing of $5.55 Million Public ... - PR Newswire
Tue, 28 Nov 2023
Seelos Therapeutics Announces Proposed Public Offering - Investing News Network
Tue, 28 Nov 2023
Seelos Therapeutics commences a public offering of its shares (NASDAQ:SEEL) - Seeking Alpha
Tue, 28 Nov 2023
Healthcare Stocks Making Moves Tuesday: RDHL, ICCM, GYRE, CDIO, AXLA, CABA, BDRX, SEEL - InvestorsObserver
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 161 (M) |
| Held by Insiders | 1.4615e+008 (%) |
| Held by Institutions | 2.8 (%) |
| Shares Short | 10,230 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | 0 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -3 % |
| Return on Assets (ttm) | 104.1 % |
| Return on Equity (ttm) | -135.8 % |
| Qtrly Rev. Growth | 1.55e+006 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | -0.5 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -35 (M) |
| PE Ratio | 0 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | -17.7 |
| Dividend | 0 |
| Forward Dividend | 8.32e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|